Notably, novel EGFR‐LFDs were identified in unreported cancer types including deletions of EGFR exon2–11 (lung cancer), exon2–15 (lung cancer), exon2–17 (lung cancer, and colorectal cancer), exon2–28 (cholangiocarcinoma) (Figure S1). This evidence concerns the gene EGFR and cholangiocarcinoma.